PAVM — PAVmed Inc

PAVmed Inc (PAVM) is a medical devices company listed on NASDAQ. It is led by Lishan Aklog M.D., based in 360 Madison Avenue, New York, NY, United States, 10017, with about 41 employees. PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Latest reported PAVM revenue for 2025-09-30 was $5.0K. Net income was -$6.0M. Revenue was down 16.7% from 2025-06-30 to 2025-09-30. PAVM currently screens at market cap $35.7M.

Use this PAVM page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PAVM quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PAVM SEC filings page. Lician reads the product cache first so this HTML stays unique to PAVmed Inc even when a live quote feed is slow.